Ignite Creation Date:
2024-05-05 @ 10:26 PM
Last Modification Date:
2024-10-26 @ 10:18 AM
Study NCT ID:
NCT01100775
Status:
COMPLETED
Last Update Posted:
2022-06-08
First Post:
2010-01-04
Brief Title:
Effects of Galantamine on Cognition
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Effects of Galantamine on Cognition
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early twenties with cognitive impairments and negative symptoms frequently emerging much earlier Such cognitive impairments and negative symptoms but much milder are also observed in high-risk groups such as relatives of schizophrenia patients who may or may not develop the full blown psychotic disorder Our study plans to recruit such non-ill subjects to test the effects of galantamine on clinicalphysiologicalcognitive measures This study serves several goals If a drug is found effective in treating subtle deficits then it will provide treatment strategy in individuals with schizophrenia spectrum personality disorders and for early intervention in schizophrenia In addition one of the difficulties of testing a drug on schizophrenia is that patients take other medications ie antipsychotic drugs that can change the effects of the test drug The proposed study will be in subjects who will not be taking antipsychotic medications Our study will be carried out in two sessions at least one month apart Subjects will be randomly assigned to the two possible order of administration the drug and then placebo or the placebo and then drug Subjects will be given a lead-in 3 days of 4mg twice a day of galantamine or placebo followed by 8 mg or placebo on the 4th day the day of testing We will administer a battery of clinicalcognitiveneurophysiological tests after the 8 mg drug dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1P50MH082999-01 | NIH | None | httpsreporternihgovquickSearch1P50MH082999-01 |